Sesquiterpenoids in cortex lycii radicis as well as preparation method and application thereof

By isolating sesquiterpenes from the rehmannia, the problem of poor treatment of diabetic neuroinflammatory in the prior art is solved, and the preparation and application of compounds with anti-neuroinflammatory activity is realized, and a new therapeutic direction is provided. .

CN119080724AActive Publication Date: 2024-12-06NANJING MEDICAL UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411189805.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-12-06
Estimated Expiration
2044-08-28

AI Technical Summary

Technical Problem

Existing diabetes treatment drugs have poor effect on the treatment of neuroinflammation, and lack significant and low side effects antidiabetic neuroinflammation drugs, especially the active ingredients of antidiabetic neuroinflammation are not identified from the rehmannia cortex.

Method used

A novel sesquiterpene compound was isolated from the dermis of the Solanaceae family, and compounds with anti-neuroinflammatory activity were prepared through specific extraction and isolation methods, which were used to treat neuroinflammatory caused by diabetes.

Benefits of technology

In vitro cell experiments show that sesquiterpenes have significant anti-neuroinflammatory activities, providing a new direction for drug development, providing effective pharmaceutical compositions and lead compounds for the treatment of diabetic neuroinflammatory, and having good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080724A_ABST
    Figure CN119080724A_ABST
Patent Text Reader

Abstract

The invention belongs to the fields of traditional Chinese medicine extraction and separation, phytochemistry and medicine, and discloses sesquiterpenoids in cortex lycii radicis. The sesquiterpenoids have anti-neuroinflammation activity, and have a good application prospect in preparation of anti-neuroinflammation drugs. The invention also discloses an application of the sesquiterpenoids in preparation of medicines for treating neuroinflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the fields of traditional Chinese medicine extraction and separation, plant chemistry and medicine, and relates to a sesquiterpenoid compound separated from the bark of Lycium bark of the Solanaceae plant, and a preparation method and application thereof. Background Art

[0002] As a chronic metabolic disease, diabetes mellitus is characterized by high morbidity and many complications. The development of diabetes is often accompanied by inflammation, and neuropathy is its most important chronic complication. If neuroinflammation is not effectively controlled, it will lead to pain, cognitive impairment, movement disorders and even symptoms such as atherosclerosis and stroke, which seriously threaten the safety of diabetic patients. At present, the effects of drugs for the treatment of diabetes are mainly focused on pain management and blood sugar control, and there are very few therapeutic drugs for diabetes-induced neuroinflammation. Therefore, it is urgent to develop anti-diabetic neuroinflammation drugs with obvious effects and low side effects.

[0003] Cortex Lycii is the dried root bark of Lycium chinese Mill. or Lycium barbarum L., a plant of the Solanaceae family. It is cold in nature and sweet in taste. It belongs to the lung, liver, and kidney meridians. It has the effects of cooling blood and removing steam, clearing the lungs and reducing fire. It is mainly used for symptoms such as yin deficiency, hot flashes, night sweats due to bone steaming, cough due to lung heat, hemoptysis, epistaxis, and internal heat and thirst. Modern studies have shown that it has pharmacological activities such as lowering blood pressure, lowering blood lipids, lowering blood sugar, inhibiting bacteria and inflammation, immunomodulating, and relieving fever and analgesia. Its single and compound preparations have been clinically used in the treatment of diabetic neuropathy. At present, the compounds found in Cortex Lycii mainly include alkaloids, flavonoids, terpenes, anthraquinones, organic acids, glycosides, and cyclic peptides. However, its active ingredients against diabetic neuritis have not yet been clearly identified.

[0004] Therefore, further analysis and development of anti-diabetic neuroinflammatory components in Radix Lycii are of great significance for the application of Radix Lycii and the development of new anti-diabetic neuroinflammatory drugs or health products. Summary of the invention

[0005] The present invention takes the bark of Lycium bark of the Solanaceae family as a research target, studies its chemical components, obtains novel sesquiterpenoid compounds, and evaluates their anti-neuroinflammatory activities, all of which have anti-neuroinflammatory activities.

[0006] To achieve the above object, the present invention adopts the following technical solution:

[0007] The sesquiterpenoid compounds with the following structure were isolated from Lycii cortex, a plant of the Solanaceae family:

[0008]

[0009]

[0010] As a preferred technical solution of the present invention, the sesquiterpenoid compound has the following structure:

[0011]

[0012] Another object of the present invention is to provide a method for preparing the sesquiterpenoid compound, comprising:

[0013] Step (1), the dried Radix Lycii Radix is ​​subjected to reflux extraction with 75-90% ethanol, the extract is concentrated under reduced pressure to remove the solvent, and an extract is adsorbed on an equal amount of diatomaceous earth, and eluted with petroleum ether, ethyl acetate and methanol in sequence, and the petroleum ether eluate, ethyl acetate eluate and methanol eluate are collected respectively, and the petroleum ether fraction, ethyl acetate fraction and methanol fraction are concentrated under reduced pressure respectively; wherein the mass volume ratio of the dried Radix Lycii Radix and 75-90% ethanol is 1:10-1:20 kg / L or g / mL;

[0014] Step (2), the ethyl acetate fraction was subjected to silica gel column chromatography, using petroleum ether-ethyl acetate system and dichloromethane-methanol system as eluents, and the same fractions were combined to obtain nine components: Fr.A to Fr.I;

[0015] Step (3), component Fr.E was subjected to silica gel column chromatography with dichloromethane-methanol system as eluent to obtain ten fractions: Fr.E1 to Fr.E10; Fr.E6 was subjected to preparative HPLC chromatography (preparative high performance liquid chromatography) to obtain compound 11; Fr.E8 was subjected to preparative HPLC chromatography to obtain compound 10; Fr.E9 was subjected to preparative HPLC chromatography to obtain compound 3, compound 4, and compound 5;

[0016] Step (4), component Fr.G was subjected to silica gel column chromatography using a dichloromethane-methanol system as an eluent to obtain twelve fractions: Fr.G1 to Fr.G12; Fr.G5 was subjected to Sephadex LH-20 gel column chromatography using a methanol-water system as an eluent to obtain six fractions: Fr.G5A to Fr.G5F; Fr.G5A was subjected to preparative HPLC chromatography to obtain compound 1 and compound 8; Fr.G10 was subjected to silica gel column chromatography using a dichloromethane-methanol system as an eluent to obtain eight fractions: Fr.G10A to G10H; Fr.G10B was subjected to preparative HPLC chromatography to obtain compound 6; Fr.G10G was subjected to preparative HPLC chromatography to obtain compound 2, compound 7, and compound 9.

[0017] In step (1), preferably, the dried Radix Lycii Radix is ​​subjected to reflux extraction with 75% ethanol.

[0018] Preferably, the mass volume ratio of the dried Radix Lycii and 75-90% ethanol is 1:20 kg / L.

[0019] The extraction was performed twice, and the time for each extraction was 2 hours.

[0020] In step (2), the petroleum ether-ethyl acetate system is petroleum ether:ethyl acetate=10:1→0:1 V / V, and the dichloromethane-methanol system is dichloromethane-methanol=15:1→5:1 V / V.

[0021] In step (3), the dichloromethane-methanol system is dichloromethane:methanol=150:1→10:1 V / V.

[0022] When isolating compound 11, the conditions for preparative HPLC chromatography were: YMC-Pack ODS-A column (model AA12S05-2510WT), mobile phase of acetonitrile: water = 50:50 V / V, and flow rate of 7-10 mL / min.

[0023] When isolating compound 10, the conditions for preparative HPLC chromatography were: YMC-Pack ODS-A column (model AA12S05-2510WT), mobile phase acetonitrile: water = 30:70 V / V, flow rate 7-10 mL / min.

[0024] When separating compound 3, compound 4, and compound 5, the conditions for preparative HPLC chromatography were: YMC-Pack ODS-A column (model AA12S05-2510WT), mobile phase acetonitrile: water = 30:70 V / V, and flow rate 7-10 mL / min.

[0025] In step (4), component Fr.G is subjected to silica gel column chromatography, and the dichloromethane-methanol system is dichloromethane:methanol=100:1→20:1V / V.

[0026] The methanol-water system is methanol:water=80:20V / V.

[0027] When separating compounds 1 and 8, the conditions for preparative HPLC chromatography were: YMC-Pack ODS-A column (model AA12S05-2510WT), mobile phase acetonitrile: water = 30:70 V / V, flow rate 7-10 mL / min.

[0028] When Fr.G10 was subjected to silica gel column chromatography, the dichloromethane-methanol system was dichloromethane:methanol=100:0→10:1V / V;

[0029] When isolating compound 6, the conditions for preparative HPLC chromatography are: YMC-Pack ODS-A column (model AA12S05-2510WT), mobile phase is acetonitrile: water = 30:70 V / V, and the flow rate is 7-10 mL / min.

[0030] When preparing compound 2, compound 7, and compound 9, the conditions for the preparative HPLC chromatography were: YMC-Pack ODS-A column (model AA12S05-2510WT), the mobile phase was acetonitrile: water = 30:70 V / V, and the flow rate was 7-10 mL / min.

[0031] Another object of the present invention is to provide the use of the sesquiterpenoid compound in the preparation of a drug for treating neuroinflammation.

[0032] Another object of the present invention is to provide the use of the sesquiterpenoid compound in the preparation of a drug for treating neuroinflammation caused by diabetes.

[0033] The present invention also provides a pharmaceutical composition with anti-neuroinflammation effect, wherein the pharmaceutical composition contains the sesquiterpenoid compound as an effective ingredient.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The present invention isolates a sesquiterpenoid compound with a novel structure from the bark of Lycium barbarum, a plant of the Solanaceae family. In vitro cell experiments show that the sesquiterpenoid compound has anti-neuroinflammatory activity and has a good application prospect in the preparation of anti-neuroinflammatory drugs. At the same time, it can be used as a lead compound, providing a strong basis for the discovery of potential new anti-neuroinflammatory drugs.

[0036] The separation method of sesquiterpenoid compounds of the present invention is simple, reliable, efficient and highly operable. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The effect of compound 1-compound 11 on the viability of BV2 cells.

[0038] Figure 2 The effects of compound 1-compound 11 (dosage concentration 10 μM) on NO release from BV2 cells stimulated by LPS; compared with the blank group, #### P<0.0001; compared with the model group, ** P<0.01, **** P<0.0001.

[0039] Figure 3The effects of compound 5 at different concentrations (2.5 μM, 5 μM, 10 μM, 20 μM) on the release of NO from BV2 cells stimulated by LPS; Compared with the blank group, ## P<0.01; compared with the model group, ** P<0.01.

[0040] Figure 4 The effect of compound 5 on the levels of TNF-α, IL-1β and IL-6 in LPS-induced BV2 cells; compared with the model group, ** P<0.01.

[0041] Figure 5 The effect of compound 5 on the expression levels of COX2 and iNOS genes in BV2 cells induced by LPS; compared with the blank group, #### P<0.0001; compared with the model group, * P<0.01, **** P<0.0001. .

[0042] Figure 6 The effect of compound 5 on the expression levels of COX2 and iNOS proteins in BV2 cells induced by LPS; compared with the blank group, #### P<0.0001; compared with the model group, * P<0.01, ** P<0.01, *** P < 0.001, **** P<0.0001. DETAILED DESCRIPTION

[0043] Example 1

[0044] Preparation of sesquiterpenoids

[0045] Sesquiterpenoid compounds are isolated and purified from the bark of Lycium bark, including:

[0046] Step (1), extracting the dried Chinese wolfberry bark (50 kg) with 1000 L 75% ethanol for 2 times, each time for 2 hours, and concentrating the extract under reduced pressure to remove the solvent to obtain an extract (7.4 kg), adsorbing the extract on an equal amount of diatomaceous earth, and eluting with petroleum ether, ethyl acetate and methanol in sequence after complete drying, collecting the petroleum ether eluate, ethyl acetate eluate and methanol eluate respectively, and concentrating under reduced pressure to obtain a petroleum ether fraction, an ethyl acetate fraction and a methanol fraction;

[0047] Step (2), the ethyl acetate fraction (775.7 g) was subjected to silica gel column chromatography, and gradient elution was performed with petroleum ether:ethyl acetate (10:1, 4:1, 7:3, 1:1, 0:1, V / V), dichloromethane:methanol (15:1, 10:1, 8:1, 5:1, V / V). The same fractions were combined to obtain 9 components, which were respectively recorded as Fr.A, Fr.B, Fr.C, Fr.D, Fr.E, Fr.F, Fr.G, Fr.H, and Fr.I;

[0048] Step (3), Fr.E (20.4 g) was subjected to silica gel column chromatography, and gradient eluted with dichloromethane-methanol (150:1, 100:1, 80:1, 50:1, 30:1, 20:1, 10:1, V / V) to obtain 10 fractions, which were respectively recorded as Fr.E1, Fr.E2, Fr.E3, Fr.E4, Fr.E5, Fr.E6, Fr.E7, Fr.E8, Fr.E9, and Fr.E10; Fr.E6 (3.5 g) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 50:50 V / V, flow rate: 7 mL / min) to prepare compound 11 (7.4 mg); Fr.E8 (1.5 g) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 30:70 V / V, flow rate: 7 mL / min) to prepare compound 10 (7.3 mg); Fr.E9 (6.6 g) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 30:70 V / V, flow rate: 7 mL / min) to prepare compound 3 (5.7 mg), compound 5 (1.9 mg), and compound 4 (4.6 mg).

[0049] Step (4), Fr.G (17.3 g) was subjected to silica gel column chromatography, and gradient eluted with dichloromethane-methanol (100:1, 80:1, 50:1, 30:1, 20:1, V / V) to obtain Fr.G1, Fr.G2, Fr.G3, Fr.G4, Fr.G5, Fr.G6, Fr.G7, Fr.G8, Fr.G9, Fr.G10, Fr.G11, and Fr.G12; Fr.G5 (1.5 g) was subjected to Sephadex chromatography LH-20 gel column chromatography, eluent methanol-water (80:20V / V), separation to obtain 6 fractions, respectively recorded as Fr.G5A, Fr.G5B, Fr.G5C, Fr.G5D, Fr.G5E, Fr.G5F; Fr.G5A (178.2 mg) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A chromatographic column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 30:70 V / V, flow rate: 7 mL / min), to prepare compound 1 (3.1 mg) and compound 8 (2.7 mg); Fr.G10 (2.5 g) was subjected to silica gel column chromatography, dichloromethane-methanol (100:0, 80:1, 50:1, 25:1, 10:1, V / V) gradient elution, and 10 fractions were separated, respectively recorded as Fr.G10A, Fr.G10B, Fr.G10C, Fr.G10D, Fr.G10E, Fr.G10F, Fr.G10G, Fr.G10H, Fr.G10B (117.8 mg) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A chromatographic column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 30:70 V / V, flow rate: 7 mL / min) was used to prepare compound 6 (2.1 mg). Fr.G10G (846.5 mg) was subjected to preparative HPLC chromatography (YMC-Pack ODS-A chromatographic column, model AA12S05-2510WT, mobile phase: acetonitrile: water = 30:70 V / V, flow rate: 7 mL / min) to prepare compound 7 (67.9 mg), compound 9 (13.7 mg) and compound 2 (2.4 mg).

[0050] Structural analysis of compounds

[0051] Compound 1

[0052]

[0053] Compound 1 is a brown powder. The UV methanol spectrum shows that the maximum absorption wavelength is at 214 nm. The IR spectrum indicates the presence of hydroxyl groups (3443 cm -1 ), carbonyl (1735cm -1 ) group, HRESI(+)MS showed 267.1593[M+H]+ (The calculated value is C 15 H 23 O4, 267.1591), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O4, molecular weight is 266, and the degree of unsaturation is 5. 1 H NMR showed four methyl proton signals δ H 1.25 (3H, s, H-12), δ H 1.23 (3H, s, H-13), δ H 1.91(3H, s, H-14), δ H 1.64 (3H, s, H-15), three pairs of methylene proton signals δ H 2.06 (1H, dd, J=17.7, 6.2Hz, H-1α), δ H 2.25(1H, m, H-1β), δ H 1.76 (1H, dd, J=13.0, 6.2Hz, H-2α), δ H 1.46 (1H, m, H-2β), δ H 2.18(1H, d, J=16.8Hz, H-4α), δ H 1.94 (1H, d, J=16.8Hz, H-4β); 13 C NMR has 5 carbons in the low field signal, namely C-5 (125.8), C-6 (131.1), C-8 (159.3), C-9 (119.7), and C-10 (172.2), indicating that there are two double bonds and one carbonyl group in compound 1, and it shows that there are 15 carbons. 1 H- 1 The presence of H-8 / H-9 in the H COSY spectrum indicates the presence of an unsaturated △8,9 double bond. In HMBC, δ H 2.06 (1H, dd, J = 17.7, 6.2 Hz, H-1α) and C-3 (74.1), C-5 (125.8) have long-range correlation; δ H 1.76 (1H, dd, J = 13.0, 6.2 Hz, H-2α) and C-4 (34.6), C-6 (131.1) have long-range correlation; δ H 2.18 (1H, d, J = 16.8 Hz, H-4α) and C-2 (26.7), C-6 (131.1) have long-range correlations, indicating the existence of a six-membered ring with a △5,6 double bond, δ H 1.25 (3H, s, H-12), δ H1.23 (3H, s, H-13) and C-3 (74.1) and C-11 (74.9) have long-range correlations, indicating that an isopropyl group is connected to the C-3 position. H 1.91 (3H, s, H-14) and C-1 (30.3), C-5 (125.8) have long-range correlations, indicating that the methyl group at position 14 is connected to C-6, δ H 7.61 (1H, d, J = 5.6 Hz, H-8) and C-10 (172.2); δ H 6.02 (1H, d, J = 5.6 Hz, H-9) and C-7 (90.8) have long-range correlations, indicating the presence of α, β-pentaunsaturated lactones, δ H 1.64 (3H, s, H-15) and C-7 (90.8), C-5 (125.8), C-8 (159.3) have long-range correlations, indicating that the methyl group at position 15 is directly connected to C-7, the α, β-five-membered unsaturated lactone is connected to the 5-position of the six-membered ring, and the last two hydroxyl groups are adjacent to C-3 and 11. Combined with HSQC, the planar structure of compound 1 was determined. Through the NOESY spectrum of H3-15 / H-4β, H-1β / H-2β, H-4β, and the calculated carbon spectrum, two correlation lines were obtained according to data processing, and the DP4 of compound 1 + The value is 100%, (3R,7S)-10 DP4 + was 0, and combined with the calculation of ECD, the absolute configuration of compound 1 was finally determined to be 3S, 7S, and it was named Lyciiterpenoid E.

[0054] Compound 2

[0055]

[0056] Compound 2 is a white powder. The UV methanol spectrum shows that the maximum absorption wavelengths are 216 and 283 nm. The IR spectrum indicates the presence of hydroxyl groups (3244 cm -1 ) and aroma (1588, 1460cm -1 ) group, HRESI(+)MS showed 235.1689[M+H] + (The calculated value is C 15 H 23 O2, 235.1693), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O3, molecular weight 234, unsaturation 5. NMR data showed similarity to Lycifuranone A, but 13 C NMR shows that there is one less carbonyl carbon than Lycifuranone A. 1In H NMR, there are two more methylene hydrogens connected to O, δ H 3.21(1H, m, H-1β), δ H 3.45 (1H, m, H-1α), H-1β / H-2β in COSY spectrum, δ in HMBC H This was confirmed by the presence of long-range correlations at 1.69 (1H, m, H-2β) and C-1 (63.0). The relative configuration of compound 2 was determined by H-3β / H-5β, H-3β / H-1β, and H-1β / H-2β in the NOESY spectrum. There was a positive Cotton effect at 210nm in the circular dichroism spectrum, and the results showed that the calculated value of 3S-2 was consistent with the experimental value, and the absolute configuration of compound 2 was determined and named Lyciiterpenoid F.

[0057] Compound 3

[0058]

[0059] Compound 3 is a colorless crystal (methanol). The UV methanol spectrum shows that the maximum absorption wavelengths are 209 and 215 nm. The IR spectrum indicates the presence of hydroxyl groups (3373, 3301, 3280 cm -1 ) and aroma (1602, 1581cm -1 ) group, HRESI(-)MS showed 249.1503[MH] - (The calculated value is C 15 H 21 O3, 249.1496), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O3, molecular weight is 250, unsaturation degree is 5. By analyzing NMR data, it is found to be similar to the compound Lyciiterpenoid C. 1 The characteristic signals provided by the HNMR (600MHz, CDCl3) spectrum revealed that the compound Lyciiterpenoid G had an additional O-linked methine signal δ compared to Lyciiterpenoid C. H 5.09 (1H, m, H-1) but lacks a pair of methylene proton signals. In the 1H-1H COSY spectrum, H-1 and H-2 are correlated, and H-7 and H-8 are correlated. At the same time, in the HMBC spectrum, δ H5.09 (1H, m, H-1) and C-2 (33.9), C-3 (75.7) have long-range correlations, which confirms that Lyciiterpenoid G has one more hydroxyl substitution at C-1 than Lyciiterpenoid C. NOESY spectra show H-2β / H-1, H-2β / H3-13 to determine the relative configuration of the compound. X-ray single crystal diffraction analysis determined its absolute configuration to be 1R, 3R, and it was named Lyciiterpenoid G.

[0060] Compound 4

[0061]

[0062] Compound 4 is a white powder. The UV methanol spectrum shows that the maximum absorption wavelengths are 205, 270, and 277 nm. The IR spectrum indicates the presence of hydroxyl groups (3349 cm -1 ) and fragrance (1622, 1579cm -1 ) group, HRESI(-)MS showed 263.1638[MH] - (The calculated value is C 16 H 23 O3, 263.1653), combined 13 C NMR (Table 3) showed that the molecular formula is C 16 H 24 O3, molecular weight is 264, unsaturation degree is 5. Through analysis, it is found that the NMR data are similar to those of compound 3, except that the substituent at position 1 is methoxy. 1 The characteristic signals provided by the H NMR (600MHz, CDCl3) spectrum revealed a methoxyl signal δ H 3.53 (3H, s, H-16), 13 C NMR (150MHz, CDCl3) showed that the compound had 16 carbon signals. H There is a long-range correlation between 3.53 (3H, s, H-16) and C-1 (75.7), and the planar structure of compound 4 is inferred. The NOESY spectrum shows H3-16 / 3-OH, H3-12 / H-2β, H-2β / H-4β, and the relative configuration of the compound is determined. There is a negative Cotton effect at 222nm in the circular dichroism spectrum, and the results show that the calculated value of (1R, 3R)-4 is consistent with the experimental value, and the absolute configuration of compound 4 is determined, and it is named Lyciiterpenoid H.

[0063] Compound 5

[0064]

[0065] Compound 5 is a yellow powder. The UV methanol spectrum shows that the maximum absorption wavelengths are 208, 269, and 277 nm. The IR spectrum indicates the presence of hydroxyl groups (3404 cm -1 ) and aroma (1565, 1510cm- 1 ) group, HRESI(+)MS showed 265.1784[M+H] + (The calculated value is C 16 H 25 O3, 265.1798), combined 13 C NMR (Table 3) showed that the molecular formula is C 16 H 24 O3, molecular weight is 264, unsaturation is 5. Comparison with NMR of compound 4 showed that it was basically consistent, but H3-16 / H-2β, H3-13, and H-4β were found in the NOESY spectrum, and the relative configuration of the compound was determined. There was a positive Cotton effect at 208nm in the circular dichroism spectrum, and the results showed that the calculated value of (1S, 3R)-5 was consistent with the experimental value, and the absolute configuration of compound 5 was determined. It is a diastereomer with compound 4 and is named Lyciiterpenoid I.

[0066] Compound 6

[0067]

[0068] Compound 6 is a brown powder. The UV methanol spectrum shows that the maximum absorption wavelengths are 217 and 266 nm. The IR spectrum indicates the presence of hydroxyl groups (3415 cm -1 ) and aroma (1592, 1541cm -1 ) group, HRESI(-)MS showed 263.1663[MH] - (The calculated value is C 16 H 23 O3, 263.1653), combined 13 C NMR (Table 3) showed that the molecular formula is C 16 H 24 O3, molecular weight is 264, unsaturation is 5. 1 H NMR and 13 C NMR comparison showed that they were basically the same, except that there was no methyl substitution at C-9 and a methyl substitution at C-7. 1 H- 1 There is a correlation between H-8 and H-9 in the H COSY spectrum; at the same time, in the HMBC spectrum, δ H 7.29 (1H, d, J = 7.9 Hz, H-9) and C-1 (76.5) have long-range correlation; δ H2.27 (3H, s, H-14) and C-6 (132.2) have long-range correlation. The planar structure of compound 6 was determined by HSQC, but due to 1 There is no 3-OH signal in the H NMR spectrum, so the relative configuration of compound 6 cannot be determined using the NOESY spectrum. By calculating the carbon spectrum and processing the data, two related straight lines are obtained: DP4 when 1-OCH3 and 3-OH are on opposite sides. + Value is 100%, DP4 on the same side + The absolute configuration of compound 6 was finally determined to be 1S, 3R by combining the calculation of ECD, and it was named Lyciiterpenoid J.

[0069] Compound 7

[0070]

[0071] Compound 7 is a colorless oil. The UV methanol spectrum shows that the maximum absorption wavelengths are 229 and 264 nm. The IR spectrum indicates the presence of hydroxyl groups (3384, 3369 cm -1 ) and fragrance (1663, 1596cm -1 ) group, HRESI(-)MS showed 249.1489[MH] - (The calculated value is C 15 H 21 O3, 249.1496), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O3, molecular weight is 250, unsaturation degree is 5. 1 H NMR and 13 C NMR comparison revealed that they were basically the same, except that there was no methoxy substitution at the C-1 position and the methyl substitution at the C-9 position was changed to hydroxymethyl. 1 The H NMR (600 MHz, CDCl3) spectrum shows a methylene signal connected to O. H 4.67 (2H, s, H-15), three pairs of methylene signals δ H 1.69 (1H, m, H-1), δ H 2.05(1H, m, H-1), δ H 2.91(2H,m,H-2),δ H 2.72 (1H, m, H-1), three methyl signals δ H 1.31 (3H, s, H-12), δ H 1.34 (3H, s, H-13), δ H2.22 (3H, s, H-14); COSY spectrum δ H 1.69 (1H, m, H-1), δ H 2.05 (1H, m, H-1) and δ H 2.91 (2H, m, H-2) is related; this is also confirmed by the HMBC spectrum, δ H 4.62 (2H, s, H-15) and C-8 (125.3), C-10 (134.0) have long-range correlations, δ H 2.07 (1H, m, H-1) and C-10 (134.0) have long-range correlation. Combined with HSQC, the planar structure of compound 7 was determined, but due to 1 There was no 3-OH signal in the H NMR spectrum, so the NOESY spectrum could not determine the relative configuration of compound 7. The absolute configuration of compound 7 was finally determined to be 3R by calculating ECD, and it was named Lyciiterpenoids K.

[0072] Compound 8

[0073]

[0074] Compound 8 is a colorless oil. The UV methanol spectrum shows that the maximum absorption wavelengths are 205 and 244 nm. The IR spectrum indicates the presence of hydroxyl groups (3412 cm -1 ) and carbonyl (1661cm -1 ) group, HRESI(-)MS showed 233.1549[MH] - (The calculated value is C 15 H 21 O2, 233.1547), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O2, molecular weight 234, unsaturation 5. NMR data show that it is similar to the spectrum of Dehydrocarissone, except that there is no methyl substitution at C-4 position, but there is a methyl substitution at C-1 position. H 2.39 (1H, m, H-6) and δ H 1.50 (1H, m, H-7) is related. Combined with δ H 2.01 (3H, brs) and C-10 (43.0) have long-range correlation; δ HThis was confirmed by the presence of long-range correlations at 6.11 (1H, brs, H-4) and C-6 (33.9). NOESY spectra showed H-9β / H3-15, H3-13, H3-13 / H-8β, H-7α / H-6α. The circular dichroism spectrum showed a negative Cotton effect at 260nm, indicating that the calculated value of (10S, 7R)-8 was consistent with the experimental value, and the absolute configuration of compound 8 was determined and named Lyciiterpenoid L.

[0075] Compound 9

[0076]

[0077] Compound 9 is a white powder. The UV methanol spectrum shows that the maximum absorption wavelength is 234 nm. The IR spectrum indicates the presence of hydroxyl groups (3449, 3371 cm -1 ) and carbonyl (1647cm -1 ) group, HRESI(-)MS showed 251.1665[MH] - (The calculated value is C 15 H 23 O3, 251.1653), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O3, molecular weight is 252, unsaturation is 4. Comparison of NMR shows that compound 9 is basically the same as carissone, except that the △4,5 double bond in carissone is changed to △1,2 in compound 9; the methyl substitution at C-4 in carissone is changed to methyl substitution at C-1 in compound 9; the methyl substitution at C-10 in carissone is changed to methyl substitution at 1-OH in compound 9; and compound 9 has an additional methyl substitution at C-15. H 1.94 (1H, m, H-9) and δ H 1.40 (1H, m, H-8) is related; δ H 5.82 (1H, s, H-2) and C-10 (73.6) have long-range correlation; δ H 1.98 (3H, brs, H-14) and C-10 (73.6) have long-range correlation; δ H 1.94 (1H, m, H-9) and C-1 (161.9) have long-range correlation; δ H1.02 (3H, s, H-15) and C-4 (48.1), C-5 (39.5), C-6 (33.4) have long-range correlations that confirm these differences. In the NOESY spectrum, H-9α / H3-15, H3-13, the relative configurations at C-5 and C-7 can be determined. Since the hydroxyl group at C-10 has no signal in NMR, two related straight lines are obtained by calculating the carbon spectrum and processing the data. When C-10 is on the same side as C-5 and 7, DP4 + 0%, and when C-10 is on the opposite side from C-5 and 7, DP4 + The relative configuration of compound 9 was 100%. The absolute configuration of compound 9 was determined to be 5S, 7S, 10S by calculating ECD, and it was named Lyciiterpenoid M.

[0078] Compound 10

[0079]

[0080] Compound 10 is a yellow oil. The UV methanol spectrum shows that the maximum absorption wavelengths are 216, 271, and 279 nm. The IR spectrum indicates the presence of hydroxyl groups (3380 cm -1 ), carbonyl (1705cm -1 ) and aroma (1600, 1575cm -1 ) group, HRESI(-)MS showed 249.1503[MH] - (The calculated value is C 15 H 21 O3, 249.1496), combined 13 C NMR (Table 3) showed that the molecular formula is C 15 H 22 O3, molecular weight of 250, unsaturation of 5. NMR data showed that the structure was similar to Lyciiterpenoid D, except that in compound 10, the C-1 position was substituted with hydroxymethyl, there was no methyl substitution at the C-5 position, while there was a methyl substitution at the C-3 position, and the C-9 position was a carbonyl carbon. 13 In C NMR, the low field shows that C-9 (213.7) is the carbonyl carbon. Combined with the HMBC δ H 1.34 (6H, s, H-11, 12) and C-9 (213.7) have long-range correlation; δ H 4.77 (2H, s, H-13) and C-2 (135.5) have long-range correlation; δ H There were long-range correlations at 2.40 (3H, s, H-15) and C-2 (135.5) and C-4 (128.3), which confirmed the structure of compound 10 and named it Lyciiterpenoid N.

[0081] Compound 11

[0082]

[0083] Compound 11 was a brown solid, as determined by HRESI(-)MS (291.1599 [MH] - ) and NMR data confirmed that its molecular formula is C 17 H 24 O4. Compound 11 1 H NMR (Table 2) and 13 The C NMR spectrum (Table 3) was similar to that of compound 10, with the only difference being the presence of an acetyl group at C-1 in compound 11 instead of the hydroxymethyl group at C-1 in compound 10, which was further confirmed by the HMBC correlations of H3-14 with C-1, H2-13 with C-2 and C-16, and H3-17 with C-16. Compound 11 was named Lyciiterpenoid O.

[0084] Table 1. Proton spectrum (CDCl3 600MHz) data of compounds 1-5

[0085]

[0086] Table 2. Hydrogen spectrum (CDCl3600 MHz) data of compounds 6-11

[0087]

[0088] Table 3. Carbon spectrum (CDCl3150 MHz) data of compounds 1-11

[0089]

[0090] Example 2

[0091] Graph Pad Prism 7 software was used to perform statistical analysis on the data, and the data were plotted and expressed as mean ± SEM. One-way ANOVA was mainly used to compare the differences between multiple groups, and Tukey's variance test was mainly used for one-way difference analysis between two groups. P < 0.05 indicated that there was a statistical difference between the groups.

[0092] Study on the anti-neuritis effect and mechanism of compounds in vitro

[0093] 1. Cell culture

[0094] BV2 cells (mouse microglial cells) were inoculated in DMEM medium containing 10% fetal bovine serum and cultured in a 5% CO2 cell culture incubator at 37°C. The medium was changed in time according to the cell adhesion.

[0095] 2. CCK-8 assay to detect the effects of compounds 1-11 on BV2 cell viability

[0096] BV2 cells were seeded in a 96-well plate, with approximately 2×10 BV2 cells in each well. 4 The 96-well plate was placed in an incubator and cultured at 5% CO2 and 37°C for 24 hours. The plate was divided into a blank group (Control group) and a drug-treated group. The culture medium of the blank group contained 1‰ DMSO, and the culture medium of the drug-treated group was a culture medium containing the sesquiterpene compound to be tested (the sesquiterpene compound was dissolved in DMSO to prepare a mother solution with a concentration of 30 mM, and then diluted to 30 μM with culture medium). The plate was cultured in an incubator at 5% CO2 and 37°C for 24 hours, the supernatant in the 96-well plate was removed, 100 μL of culture medium containing 10 μL CCK-8 was added to each well, and the plate was incubated at 5% CO2 and 37°C for 2 hours. The absorbance of each well was measured at 490 nm using an enzyme reader, and the cell viability of the compound was calculated by the absorbance.

[0097] The results are as follows Figure 1 As shown, at a dosage concentration of 30 μM, compounds 1 to 11 had no obvious toxicity to BV2 cells.

[0098] 3. Griess method to measure the effects of compounds 1-11 on the NO content in LPS-induced BV2 cells

[0099] A blank group (Control group), a model group (Model group, LPS 1 μg / mL), an LPS (1 μg / mL) + compound group, and an LPS (1 μg / mL) + control group were set up. The sesquiterpenoid compounds and curcumin to be tested were prepared into a 30 mM stock solution with DMSO and then diluted to 10 μM with culture medium.

[0100] BV2 cells were grown at 3 × 10 4The cells were inoculated in a 96-well plate at a density of 10 cells / well, and the cells were cultured overnight. The cell operations of each group were as follows: the LPS+compound group was replaced with a medium containing the sesquiterpene compound to be tested (10 μM), and after 2 hours of culture, it was replaced with a medium containing LPS (1 μg / mL) for stimulation, and continued to be cultured for 24 hours; the LPS+control group was replaced with a medium containing curcumin (10 μM), and after 2 hours of culture, it was replaced with a medium containing LPS (1 μg / mL), and continued to be cultured for 24 hours; the Model group was replaced with a fresh medium, and after 2 hours of culture, it was replaced with a medium containing LPS (1 μg / mL), and continued to be cultured for 24 hours; the Control group was replaced with a fresh medium for culture, and the total culture was 26 hours. The cell supernatant was then collected, and the NO content was detected by the Griess method, and the OD value was detected at 540 nm using an enzyme marker.

[0101] like Figure 2 As shown, compounds 1-11 were able to inhibit the abnormal release of NO induced by LPS at a concentration of 10 μM, among which compound 5 showed the best activity.

[0102] According to the above experiment, the effect of different concentrations (2.5 μM, 5 μM, 10 μM, 20 μM) of compound 5 on the release of NO from LPS-stimulated BV2 cells was investigated. The results are shown in Figure 3 Compound 5 inhibited the abnormal release of NO in BV2 cells in a dose-dependent manner, and its effect at 10 μM was comparable to that of curcumin (dosage concentration 20 μM).

[0103] 4. ELISA kit to test anti-inflammatory factors

[0104] A blank group (Control group), a model group (1 μg / mL LPS), an LPS+compound 5 group (1 μg / mL LPS, 2.5, 5, 10 μM compound 5) and an LPS+control group (1 μg / mL LPS, 20 μM curcumin) were set up; the sesquiterpene compounds and curcumin to be tested were prepared into a 10 mM stock solution with DMSO and then diluted to the corresponding concentration with culture medium.

[0105] BV2 cells were grown at 5 × 10 4The cells were inoculated in a 96-well plate at a density of 10 cells / mL. After overnight culture, the LPS+compound 5 group was replaced with a culture medium containing the sesquiterpene compounds to be tested, and after 2 h of culture, it was replaced with a culture medium containing LPS (1 μg / mL) for stimulation and continued to be cultured for 24 h; the LPS+control group was replaced with a culture medium containing curcumin (20 μM), and after 2 h of culture, it was replaced with a culture medium containing LPS (1 μg / mL), and continued to be cultured for 24 h; the model group was replaced with a fresh culture medium, and after 2 h of culture, it was replaced with a culture medium containing LPS (1 μg / mL), and continued to be cultured for 24 h; the Control group was replaced with a fresh culture medium for culture, and the total culture was 26 h; the cell supernatant was collected, packaged at 120 μL / tube, and stored in a -20°C refrigerator, and inflammatory factors were determined using an ELISA kit (Hunan Aifang Biotechnology Co., Ltd.).

[0106] Add the standard and sample to the bottom of the ELISA plate wells according to the grouping, seal the plate with a sealing film, and incubate at 37°C for 30 minutes; remove the sealing film, discard the liquid, fill each well with washing solution, let it stand for 30 seconds and discard it, repeat 5 times, let it stand and dry; except for the blank group, add 50μL of enzyme label reagent to each well, incubate at 37°C for 30 minutes, discard the liquid, fill each well with washing solution, let it stand for 30 seconds and discard it, repeat 5 times, let it stand and dry; first add 50μL of color developer A to each well, then add 50μL of color developer B, gently shake and mix, color at 37°C in the dark for 10 minutes (blue turns yellow immediately at this time), and then add stop solution to stop the reaction. Use the blank group culture medium well to zero, and within 15 minutes after adding the stop solution, measure the absorbance (OD value) of each well in sequence at a wavelength of 450nm. Use the concentration and OD value of the standard to calculate the standard curve, substitute the OD value of the sample into the standard curve, calculate the sample concentration, and then multiply it by the dilution factor to get the actual concentration of the sample.

[0107] The results are as follows Figure 4 As shown, compared with the Control group, LPS significantly stimulated the release of TNF-, IL-1β and IL-6 in BV2 cells, while administration of compound 5 (2.5, 5, 10 μM) could inhibit the release of TNF-, IL-1β and IL-6 in a dose-dependent manner.

[0108] 5. Real-time fluorescence quantitative PCR experiment

[0109] Real-time fluorescence quantitative PCR was used to analyze the effect of compound 5 on the gene expression of inflammatory factors in LPS-induced BV2 cells.

[0110] BV2 cells were grown at 3 × 10 5The cells were inoculated in a 24-well plate at a density of 10 cells / well. The grouping was the same as that of the "ELISA kit for anti-inflammatory factor test", with the only difference being that the culture was continued for 6 hours after the addition of LPS. First, the total RNA was extracted, and the sample premix was prepared according to Table 4. Then, the program "25°C, 5min→42°C, 30min→85°C, 5min" was set on the reaction area of ​​the thermal cycler for reverse transcription. The samples obtained by the reverse transcription reaction were stored in a refrigerator at -20°C or -80°C. Real-time fluorescence quantitative PCR experiments were performed, and the primer design was shown in Table 5, and the PCR reaction system was shown in Table 6.

[0111] The extraction process of total RNA is as follows:

[0112] (1) After the cells were cultured for 6 hours, the culture medium was discarded, the 24-well plate was rinsed with pre-cooled PBS, 1 mL of Trizol was added, the plate was lysed on ice for 5 minutes, inverted and allowed to stand for another 5 minutes, 200 μL of chloroform was added, the lid was tightly closed and vortexed for 15 seconds, the plate was allowed to stand at room temperature for 2-3 minutes, the plate was allowed to stand on ice for 15 minutes, and the plate was centrifuged at 12,000 rpm for 20 minutes at 4°C. 350 μL of the supernatant was aspirated into a new enzyme-free EP tube;

[0113] (2) Add an equal volume of isopropanol, gently invert the tube 10 times, and place on ice for 10 min. Centrifuge at 12,000 rpm at 4°C for 20 min, discard the supernatant, and the precipitate at the bottom of the tube is RNA.

[0114] (3) Slowly add 500 μL of 75% ethanol (prepared with DEPC water and stored at 4 degrees) along the wall, flick the EP tube, centrifuge at 12,000 rpm for 5 min at 4°C, repeat once, slowly discard the ethanol, dry at room temperature for 10 min until translucent, add 20 μL of DEPC water to dissolve, and use Nanodrop to detect RNA purity.

[0115] Table 4. Reverse transcription reaction system

[0116]

[0117] Table 5. QRT-PCR primer sequences

[0118]

[0119] Table 6. PCR amplification reaction system

[0120]

[0121] Depend on Figure 5It can be seen that compared with the Control group, after 6 hours of LPS treatment of BV2 cells, the gene expression levels of COX2 and iNOS increased significantly, while compound 5 (2.5, 5, 10 μM) was given 2 hours in advance, and the above gene expression levels showed a concentration-dependent decrease compared with the model group. In addition, compared with curcumin, compound 5 showed a stronger inhibitory effect on COX2 and iNOS gene expression at a lower concentration.

[0122] 6. Western blot experiment

[0123] BV2 cells were cultured at 1 × 10 6 The cells were inoculated in a 6-well plate at a density of 100 cells / mL and grouped as in the "ELISA kit for anti-inflammatory factor experiment". After 24 hours of corresponding treatment of the cells according to the grouping, the culture medium was discarded, the 6-well plate was rinsed with pre-cooled PBS, 120 μL RIPA was added on ice and lysed on ice for 30 minutes, and then the cells of each group were collected by cell scraping, centrifuged at 12000 rpm at 4°C for 20 minutes, and part of the supernatant was taken to determine the protein concentration by the BCA method, and an appropriate volume of PBS and protein loading buffer were added to the remaining supernatant to adjust the protein concentration of each group of samples to be consistent, heated in a 100°C metal bath for 10 minutes to denature the protein, and the protein was stored at -20°C.

[0124] After electrophoresis for 90 minutes at room temperature, the protein was transferred to the PVDF membrane by electrophoresis in an ice-water bath for 60 minutes. The PVDF membrane was blocked for 90 minutes at room temperature and washed 3 times with TBST. The primary antibody was incubated overnight at 4°C and washed 3 times with TBST. The secondary antibody was incubated for 1 hour at room temperature and washed 3 times with TBST. Finally, the entire PVDF membrane surface was covered with ECL working solution, reacted at room temperature for 1 minute, and the membrane was placed in a fully automatic chemiluminescence imaging analysis system to obtain the final band results.

[0125] The results are as follows Figure 6 As shown, under LPS stimulation, the expression levels of COX2 and iNOS proteins in BV2 cells were significantly increased compared with the blank group, while compound 5, when acted 2 h in advance, downregulated the expression levels of COX2 and iNOS proteins in a dose-dependent manner.

[0126] In summary, the sesquiterpenoid compounds of the present invention have good application prospects in the preparation of drugs for treating neuroinflammation, and provide a reference for clinical discovery of potential anti-neuroinflammation lead compounds from Lycium bark.

Claims

1. Sesquiterpenoid compounds with the following structure:

2. Sesquiterpenoid compounds with the following structure:

3. The method for preparing the sesquiterpenoid compound according to claim 1, Features: include: Step (1), the dried Chinese wolfberry bark is subjected to reflux extraction with 75-90% ethanol, the extract is concentrated under reduced pressure to remove the solvent, and an extract is adsorbed on an equal amount of diatomaceous earth, and eluted with petroleum ether, ethyl acetate and methanol in sequence, and the petroleum ether eluate, ethyl acetate eluate and methanol eluate are collected respectively, and are concentrated under reduced pressure to obtain a petroleum ether fraction, an ethyl acetate fraction and a methanol fraction; Step (2), the ethyl acetate fraction was subjected to silica gel column chromatography, using petroleum ether-ethyl acetate system and dichloromethane-methanol system as eluents, and the same fractions were combined to obtain nine components: Fr.A to Fr.I; Step (3), component Fr.E was subjected to silica gel column chromatography with dichloromethane-methanol system as eluent to obtain ten fractions: Fr.E1 to Fr.E10; Fr.E6 was subjected to preparative HPLC chromatography to obtain compound 11; Fr.E8 was subjected to preparative HPLC chromatography to obtain compound 10; Fr.E9 was subjected to preparative HPLC chromatography to obtain compound 3, compound 4, and compound 5; Step (4), component Fr.G was subjected to silica gel column chromatography using a dichloromethane-methanol system as an eluent to obtain twelve fractions: Fr.G1 to Fr.G12; Fr.G5 was subjected to Sephadex LH-20 gel column chromatography using a methanol-water system as an eluent to obtain six fractions: Fr.G5A to Fr.G5F; Fr.G5A was subjected to preparative HPLC chromatography to obtain compound 1 and compound 8; Fr.G10 was subjected to silica gel column chromatography using a dichloromethane-methanol system as an eluent to obtain eight fractions: Fr.G10A to G10H; Fr.G10B was subjected to preparative HPLC chromatography to obtain compound 6; Fr.G10G was subjected to preparative HPLC chromatography to obtain compound 2, compound 7, and compound 9.

4. The method for preparing the sesquiterpenoid compound according to claim 3, Features: In step (1), the mass volume ratio of the dried Radix Lycii and 75-90% ethanol is 1:10-1:20 kg / L or g / mL.

5. The method for preparing the sesquiterpenoid compound according to claim 3, Features: In step (2), the petroleum ether-ethyl acetate system is petroleum ether:ethyl acetate=10:1→0:1 V / V, and the dichloromethane-methanol system is dichloromethane-methanol=15:1→5:1 V / V.

6. The method for preparing the sesquiterpenoid compound according to claim 3, Features: In step (3), the dichloromethane-methanol system is dichloromethane:methanol=150:1→10:1 V / V; When isolating compound 11, the conditions for preparative HPLC chromatography were as follows: chromatographic column, mobile phase acetonitrile: water = 50:50 V / V, flow rate 7-10 mL / min; When isolating compound 10, the conditions for preparative HPLC chromatography were as follows: chromatographic column, mobile phase acetonitrile:water = 30:70 V / V, flow rate 7-10 mL / min; When separating compound 3, compound 4, and compound 5, the conditions for preparative HPLC chromatography were as follows: chromatographic column, mobile phase of acetonitrile:water=30:70 V / V, and flow rate of 7-10 mL / min.

7. The method for preparing the sesquiterpenoid compound according to claim 3, Features: In step (4), component Fr.G is subjected to silica gel column chromatography, and the dichloromethane-methanol system is dichloromethane:methanol=100:1→20:1V / V; The methanol-water system is methanol: water = 80:20 V / V; When separating compounds 1 and 8, the conditions for preparative HPLC chromatography were as follows: chromatographic column, mobile phase acetonitrile: water = 30:70 V / V, flow rate 7-10 mL / min; When Fr.G10 was subjected to silica gel column chromatography, the dichloromethane-methanol system was dichloromethane:methanol=100:0→10:1V / V; When isolating compound 6, the conditions for preparative HPLC chromatography were as follows: chromatographic column, mobile phase acetonitrile:water = 30:70 V / V, flow rate 7-10 mL / min; When preparing compound 2, compound 7, and compound 9, the conditions for the preparative HPLC chromatography are: chromatographic column, mobile phase acetonitrile:water=30:70V / V, and flow rate 7-10mL / min.

8. Use of the sesquiterpenoid compound according to claim 1 or 2 in the preparation of a medicament for treating neuroinflammation.

9. Use of the sesquiterpenoid compound according to claim 1 or 2 in the preparation of a medicament for treating neuroinflammation induced by diabetes.

10. A pharmaceutical composition having anti-neuroinflammatory effect, Features: The pharmaceutical composition comprises the sesquiterpenoid compound according to claim 1 or 2 and a pharmaceutically acceptable carrier or excipient.

Citation Information

Patent Citations

  • Cortex lycii radicis sesquiterpene composition as well as preparation method and application thereof

    CN115784845A

  • Sesquiterpene coumarin compound in ferula sinkiang as well as preparation method and application of sesquiterpene coumarin compound

    CN116514757A

  • Sesquiterpenoids derivative as well as preparation method and application thereof

    CN117843655A